Provided by Tiger Trade Technology Pte. Ltd.

Axsome Therapeutics

156.35
-7.9150-4.82%
Post-market: 156.350.00000.00%19:21 EDT
Volume:680.80K
Turnover:107.84M
Market Cap:8.00B
PE:-42.49
High:163.89
Open:163.89
Low:155.56
Close:164.27
52wk High:191.50
52wk Low:86.99
Shares:51.15M
Float Shares:41.87M
Volume Ratio:1.05
T/O Rate:1.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6800
EPS(LYR):-3.6821
ROE:-252.11%
ROA:-16.81%
PB:90.58
PE(LYR):-42.46

Loading ...

Reaffirming Axsome Therapeutics as a Buy on Robust Commercial Growth and Advancing Late‑Stage Pipeline, With a Raised $260 Price Target

TIPRANKS
·
Jan 20

Axsome Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Jan 17

Mizuho Securities Keeps Their Buy Rating on Axsome Therapeutics (AXSM)

TIPRANKS
·
Jan 16

Axsome Therapeutics Launches Phase 3 FORWARD Trial of AXS-14 for Fibromyalgia

Reuters
·
Jan 15

Axsome Therapeutics Initiates Forward Phase 3 Trial of Axs-14 for the Management of Fibromyalgia

THOMSON REUTERS
·
Jan 15

Axsome Therapeutics Is Maintained at Overweight by Wells Fargo

Dow Jones
·
Jan 13

Axsome Therapeutics price target raised to $209 from $157 at Baird

TIPRANKS
·
Jan 13

U.S. RESEARCH ROUNDUP-Cencora, Kennametal, Regeneron Pharmaceuticals

Reuters
·
Jan 13

Axsome Therapeutics Expects 65% Rise in Q4 Product Revenue

MT Newswires Live
·
Jan 12

Axsome Therapeutics Reports Strong Preliminary 2025 Revenue Growth

TIPRANKS
·
Jan 12

Axsome Therapeutics reports preliminary Q4 revenue $196M, consensus $187.02M

TIPRANKS
·
Jan 12

Press Release: Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue

Dow Jones
·
Jan 12

Axsome Therapeutics Cut to Equal-Weight From Overweight by Morgan Stanley

Dow Jones
·
Jan 08

RBC Raises Price Target on Axsome Therapeutics to $212 From $198, Keeps Outperform Rating

MT Newswires Live
·
Jan 08

Axsome Therapeutics CEO Herriot Tabuteau Reports Sale of Common Shares

Reuters
·
Jan 08

Axsome Therapeutics Is Maintained at Buy by UBS

Dow Jones
·
Jan 07

UBS Adjusts Price Target on Axsome Therapeutics to $248 From $163, Maintains Buy Rating

MT Newswires Live
·
Jan 06

U.S. RESEARCH ROUNDUP-Brunswick, Parker-Hannifin, XPLR Infrastructure

Reuters
·
Jan 06

Axsome Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jan 05

Director Mark E. Saad Reports Disposal of Axsome Therapeutics Inc. Common Shares

Reuters
·
Jan 03